Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
Nexalin Technology (Nasdaq: NXL) announces an upcoming investor webinar scheduled for November 5th, 2024, at 4:15 p.m. ET. CEO Mark White will present the company's progress on their non-invasive deep brain stimulation device and the new Gen-3 HALO™ Clarity & Virtual Clinic model. The presentation will highlight clinical data showing improvements in treating insomnia, PTSD, and traumatic brain injuries. The company operates in a market projected to reach $537 billion by 2030. The event includes a live Q&A session and is free to attend with registration.
Nexalin Technology (Nasdaq: NXL) annuncia un prossimo webinar per gli investitori, programmato per il 5 novembre 2024, alle 16:15 ET. Il CEO Mark White presenterà i progressi dell'azienda sul loro dispositivo di stimolazione cerebrale profonda non invasivo e il nuovo Gen-3 HALO™ Clarity & Virtual Clinic model. La presentazione metterà in evidenza i dati clinici che mostrano i miglioramenti nel trattamento dell'insonnia, del PTSD e delle lesioni cerebrali traumatiche. L'azienda opera in un mercato che si prevede raggiunga $537 miliardi entro il 2030. L'evento include una sessione di domande e risposte dal vivo ed è gratuito con registrazione.
Nexalin Technology (Nasdaq: NXL) anuncia un próximo seminario web para inversores programado para el 5 de noviembre de 2024, a las 4:15 p.m. ET. El CEO Mark White presentará los avances de la empresa en su dispositivo de estimulación cerebral profunda no invasivo y el nuevo Gen-3 HALO™ Clarity & Virtual Clinic model. La presentación destacará los datos clínicos que muestran mejoras en el tratamiento del insomnio, el PTSD y las lesiones cerebrales traumáticas. La empresa opera en un mercado que se proyecta que alcance $537 mil millones para 2030. El evento incluirá una sesión de preguntas y respuestas en vivo y es gratuito con registro.
넥살린 테크놀로지 (Nasdaq: NXL)는 2024년 11월 5일 오후 4시 15분 ET에 예정된 투자자 웨비나를 발표합니다. CEO 마크 화이트는 비침습적 심부 뇌 자극 장치에 대한 회사의 진행 상황과 새로운 Gen-3 HALO™ Clarity & Virtual Clinic model을 소개합니다. 발표에서는 불면증, PTSD, 외상성 뇌 손상 치료에서의 개선 사항을 보여주는 임상 데이터를 강조할 것입니다. 이 회사는 2030년까지 5,370억 달러 규모에 이를 것으로 예상되는 시장에서 운영되고 있습니다. 이 이벤트에는 라이브 Q&A 세션이 포함되어 있으며, 등록 시 무료로 참석할 수 있습니다.
Nexalin Technology (Nasdaq: NXL) annonce un webinaire pour investisseurs prévu pour le 5 novembre 2024 à 16h15 ET. Le PDG Mark White présentera les progrès de l'entreprise sur leur dispositif de stimulation cérébrale profonde non invasive et le nouveau Gen-3 HALO™ Clarity & Virtual Clinic model. La présentation mettra en lumière des données cliniques montrant des améliorations dans le traitement de l'insomnie, du PTSD et des lésions cérébrales traumatiques. L'entreprise opère sur un marché qui devrait atteindre 537 milliards de dollars d'ici 2030. L'événement inclut une session de questions-réponses en direct et est gratuit avec inscription.
Nexalin Technology (Nasdaq: NXL) kündigt ein bevorstehendes Investoren-Webinar an, das für den 5. November 2024 um 16:15 Uhr ET geplant ist. CEO Mark White wird den Fortschritt des Unternehmens bei ihrem nicht-invasiven tiefen Hirnstimulationsgerät und dem neuen Gen-3 HALO™ Clarity & Virtual Clinic model präsentieren. Die Präsentation wird klinische Daten hervorheben, die Verbesserungen bei der Behandlung von Schlaflosigkeit, PTSD und traumatischen Gehirnverletzungen zeigen. Das Unternehmen agiert auf einem Markt, der voraussichtlich bis 2030 537 Milliarden US-Dollar erreichen wird. Die Veranstaltung beinhaltet eine Live-Q&A-Session und ist mit Registrierung kostenlos.
- Operating in a market projected to reach $537 billion by 2030
- Clinical data shows improvements in treating multiple conditions
- Expanding product line with new Gen-3 HALO™ Clarity & Virtual Clinic model
- None.
HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin’s solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries—conditions that affect millions but have limited effective treatments—positioning Nexalin as an emerging leader in a market poised for substantial growth, projected to reach
To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_79QJQ0XvS2KGxWU5Vw8THw#/registration
Questions can be pre-submitted to NXL@redchip.com or online during the live event.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
NXL@redchip.com
FAQ
When is Nexalin Technology (NXL) hosting its investor webinar?
What will be discussed in Nexalin's (NXL) November 2024 investor webinar?